AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,589.00
-20.00 (-0.36%)
At close: 4:39PM BST
Stock chart is not supported by your current browser
Previous close5,609.00
Open5,613.00
Bid5,525.00 x 6100
Ask5,606.00 x 13000
Day's range5,540.00 - 5,642.00
52-week range4,260.00 - 5,665.00
Volume1,337,820
Avg. volume2,253,199
Market cap70.794B
Beta0.96
PE ratio (TTM)25.24
EPS (TTM)221.40
Earnings date26 Jul 2018
Forward dividend & yield2.02 (3.91%)
Ex-dividend date2018-02-15
1y target est72.60
  • Analysts’ Recommendations for Stryker and Its Peers in July
    Market Realist9 hours ago

    Analysts’ Recommendations for Stryker and Its Peers in July

    The SG&A expenses incurred by Stryker (SYK) are expected to increase 9.4% from $1.05 billion in the second quarter of 2017 to $1.15 billion in the second quarter. Total operating expenses incurred by Stryker are expected to reach $1.42 billion for the second quarter, compared with $1.49 billion for the second quarter of 2017. Analysts expect Stryker (SYK) to report net income of $549.25 million in the second quarter compared with $391.0 million in the second quarter of 2017, an increase of 40.47%.

  • What Analysts Think about AstraZeneca and Peers in July
    Market Realist15 hours ago

    What Analysts Think about AstraZeneca and Peers in July

    AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017, a decrease of 1.56%. AstraZeneca is expected to report net income per share of $0.04 in Q2 2018 as compared with $0.19 in Q2 2017. Four of the total six analysts covering AstraZeneca in July 2018 have given it a “buy” or higher rating.

  • What to Expect from AstraZeneca’s Second-Quarter Earnings
    Market Realist16 hours ago

    What to Expect from AstraZeneca’s Second-Quarter Earnings

    AstraZeneca (AZN), the maker of key products like Lynparza, Tagrisso, Imfinzi, Brilinta, and Farxiga, is expected to report Q2 2018 earnings on July 26. AstraZeneca’s revenues are expected to increase 0.77% from $5.05 billion in Q2 2017 to $5.09 billion in Q2 2018. In fiscal 2017, AstraZeneca generated $22.46 billion in revenues.

  • Reuters17 hours ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters - UK Focus17 hours ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters3 days ago

    AstraZeneca to stockpile drugs as Brexit 'safety net'

    AstraZeneca (AZN.L) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way. A company spokesman said on Wednesday that AstraZeneca currently held several months of supplies of such medicines and this was being increased for products on both sides of the Channel.

  • Reuters - UK Focus3 days ago

    AstraZeneca to stockpile drugs as Brexit 'safety net'

    AstraZeneca (NYSE: AZN - news) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way.

  • Forget the State Pension: AstraZeneca could help you to enjoy a prosperous retirement
    Fool.co.uk4 days ago

    Forget the State Pension: AstraZeneca could help you to enjoy a prosperous retirement

    AstraZeneca plc (LON: AZN) appears to offer strong dividend growth potential.

  • These 2 FTSE 100 stocks could give you a comfortable retirement
    Fool.co.uk5 days ago

    These 2 FTSE 100 stocks could give you a comfortable retirement

    Your retirement portfolio could benefit significantly from these FTSE 100 (INDEXFTSE: UKX) stocks.

  • AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer
    Market Realist7 days ago

    AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer

    On June 27, AstraZeneca (AZN) and Merck (MRK) reported positive data for their Phase 3 Lynparza trial, SOLO-1, a randomized, double-blind, placebo-controlled trial for ovarian cancer. The drug met the primary endpoint of progression-free survival in women with BRCA1-mutated advanced ovarian cancer. Lynparza is the only PARP2 inhibitor to show significant activity in a first-line maintenance setting. Based on this data, the two companies plan to initiate discussions with authorities for regulatory submissions.

  • MarketWatch8 days ago

    Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

    Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

  • FTSE 100 recovers, driven by defensives, as trade nerves ebb
    Reuters8 days ago

    FTSE 100 recovers, driven by defensives, as trade nerves ebb

    By Helen Reid LONDON (Reuters) - British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE ...

  • Reuters - UK Focus8 days ago

    FTSE 100 recovers, driven by defensives, as trade nerves ebb

    British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE 100 ended the session up 0.8 ...

  • The Wall Street Journal14 days ago

    [$$] Difficult Conversation: When the Harasser Is a Client

    At many companies, client relationships are the most difficult to police – and the most important to protect. A former vice president at market-data firm Research Now SSI alleged in a lawsuit filed in April that a senior executive from the airline Virgin America, Stuart Dinnis, began kissing and groping her without warning in a hotel elevator late at night during a 2016 travel-industry conference. Earlier that day, she and her boss had discussed Mr. Dinnis, then Virgin America’s director of loyalty, as an important client to cultivate during the conference.

  • Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
    Zacks15 days ago

    Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

    Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

  • Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
    Reuters15 days ago

    Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

    AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumors before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumors.

  • Reuters15 days ago

    Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

    AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.

  • AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan
    Market Realist18 days ago

    AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan

    AstraZeneca (AZN) received two key regulatory approvals this week in Japan. On July 2, its immunotherapy drug Imfinzi was approved by Japan’s Ministry of Health, Labour and Welfare for lung cancer patients whose disease was inoperable and has advanced locally but has not widely spread throughout the body. It has been approved as a maintenance therapy after definitive chemoradiation therapy (or CRT).

  • AstraZeneca's Two New Cancer Drugs Get Approval in Japan
    Zacks18 days ago

    AstraZeneca's Two New Cancer Drugs Get Approval in Japan

    AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

  • AstraZeneca wins speedy approvals for cancer drugs in Japan
    Reuters19 days ago

    AstraZeneca wins speedy approvals for cancer drugs in Japan

    LONDON (Reuters) - AstraZeneca (AZN.L) has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. ...

  • Reuters - UK Focus19 days ago

    AstraZeneca wins speedy approvals for cancer drugs in Japan

    AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. The decisions by the ...

  • AstraZeneca, Merck eye $1 billion boost from cancer drug success
    Reuters24 days ago

    AstraZeneca, Merck eye $1 billion boost from cancer drug success

    AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co under a deal struck last year. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations.

  • Reuters - UK Focus24 days ago

    AstraZeneca, Merck eye $1 bln boost from cancer drug success

    AstraZeneca (NYSE: AZN - news) 's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations. Its latest success could expand the number of women with newly diagnosed ovarian cancer who are suitable for the drug by 30-50 percent, AstraZeneca (Swiss: AZN.SW - news) believes.

  • Reuters - UK Focus24 days ago

    AstraZeneca, Merck eye wider cancer drug use after study success

    AstraZeneca (NYSE: AZN - news) 's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co (Swiss: MRK-USD.SW - news) under a deal struck last year. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations.

  • Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines
    Motley Fool27 days ago

    Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines

    These drugmakers arguably have the strongest pipelines. But are they all great stocks to buy?

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes